RxDoctor Payments Data

Jevon Johnson, MD

Psychiatry · Modesto, CANPI 1154512036

Payments from drug & device makers

$106,445in general payments, 2019–2025

Across 517 payments — averaging $205.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Otsuka America Pharmaceutical, Inc.$84K
  • Indivior Inc.$15K
  • Johnson & Johnson$1K
  • Otsuka Pharmaceutical Development & Commercialization, Inc.$1K
  • Teva Pharmaceuticals USA, Inc.$877
  • Vanda Pharmaceuticals Inc.$816
  • plus $3K from 8 others

What the payments were for

  • Consulting fees$4,9865%
  • Speaking & faculty fees$81,08476%
  • Travel & lodging$9,0108%
  • Food & beverage$11,01410%
  • Education$3510%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$106,445 in reported general payments places this provider in the 95th percentile of 4,954 psychiatry providers in California.

See all psychiatry providers in California

Medicare billing

Part B allowed, 2024
$2,797
Medicare patients
14
Services billed
32

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Abilify MaintenaAripiprazole15$43,464
LybalviOlanzapine/Samidorphan Malate14$22,614
VraylarCariprazine Hcl13$18,044
Clozapine42$2,647
Divalproex Sodium ErDivalproex Sodium40$2,268
Olanzapine29$1,443
Paliperidone ErPaliperidone11$1,008
Ziprasidone Hcl14$926
Lurasidone Hcl14$919
Buspirone Hcl28$662
Benztropine Mesylate39$601
Risperidone19$474
Haloperidol13$367
Quetiapine Fumarate34$339
Clonazepam25$301

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Otsuka America Pharmaceutical, Inc.Abilify Maintena$83,957$43,46415 claims
Alkermes, Inc.Lybalvi$755$22,61414 claims
AbbVieVraylar$532$18,04413 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,954 psychiatry providers in California.

Other psychiatry in Modesto

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →